Type 1 Interferons and the Virus-Host Relationship: A Lesson in Détente
Top Cited Papers
- 12 May 2006
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 312 (5775) , 879-882
- https://doi.org/10.1126/science.1125676
Abstract
The interface between an infectious agent and its host represents the ultimate battleground for survival: The microbe must secure a niche for replication, whereas the host must limit the pathogen's advance. Among the host's arsenal of antimicrobial factors, the type 1 interferons (IFNs) induce potent defense mechanisms against viruses and are key in the host-virus standoff. Viruses have evolved multiple tricks to avoid the immediate antiviral effects of IFNs and, in turn, hosts have adapted use of this innate cytokine system to galvanize multiple additional layers of immune defense. The plasticity that exists in these interactions provides us with a lesson in détente.Keywords
This publication has 54 references indexed in Scilit:
- TLR signalingCell Death & Differentiation, 2006
- Recognition of Cytosolic DNA Activates an IRF3-Dependent Innate Immune ResponseImmunity, 2006
- A Toll-like receptor–independent antiviral response induced by double-stranded B-form DNANature Immunology, 2005
- Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virusNature, 2005
- VISA Is an Adapter Protein Required for Virus-Triggered IFN-β SignalingMolecular Cell, 2005
- Identification and Characterization of MAVS, a Mitochondrial Antiviral Signaling Protein that Activates NF-κB and IRF3Cell, 2005
- IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon inductionNature Immunology, 2005
- Viruses Evade the Immune System through Type I Interferon-Mediated STAT2-Dependent, but STAT1-Independent, SignalingImmunity, 2005
- The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responsesNature Immunology, 2004
- Interferon β in multiple sclerosis: is IL-12 suppression the key?Immunology Today, 2000